175 related articles for article (PubMed ID: 38281033)
1. Noninvasive serum N-glycans associated with ovarian cancer diagnosis and precancerous lesion prediction.
Liu S; Tu C; Zhang H; Huang H; Liu Y; Wang Y; Cheng L; Liu BF; Ning K; Liu X
J Ovarian Res; 2024 Jan; 17(1):26. PubMed ID: 38281033
[TBL] [Abstract][Full Text] [Related]
2. The ascites N-glycome of epithelial ovarian cancer patients.
Biskup K; Braicu EI; Sehouli J; Tauber R; Blanchard V
J Proteomics; 2017 Mar; 157():33-39. PubMed ID: 28188862
[TBL] [Abstract][Full Text] [Related]
3. N-linked glycan structures and their expressions change in the blood sera of ovarian cancer patients.
Alley WR; Vasseur JA; Goetz JA; Svoboda M; Mann BF; Matei DE; Menning N; Hussein A; Mechref Y; Novotny MV
J Proteome Res; 2012 Apr; 11(4):2282-300. PubMed ID: 22304416
[TBL] [Abstract][Full Text] [Related]
4. Characterization of IgG N-glycome profile in colorectal cancer progression by MALDI-TOF-MS.
Liu S; Cheng L; Fu Y; Liu BF; Liu X
J Proteomics; 2018 Jun; 181():225-237. PubMed ID: 29698801
[TBL] [Abstract][Full Text] [Related]
5. The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses.
Lenhard M; Stieber P; Hertlein L; Kirschenhofer A; Fürst S; Mayr D; Nagel D; Hofmann K; Krocker K; Burges A
Clin Chem Lab Med; 2011 Sep; 49(12):2081-8. PubMed ID: 21923475
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.
Karlsen MA; Sandhu N; Høgdall C; Christensen IJ; Nedergaard L; Lundvall L; Engelholm SA; Pedersen AT; Hartwell D; Lydolph M; Laursen IA; Høgdall EV
Gynecol Oncol; 2012 Nov; 127(2):379-83. PubMed ID: 22835718
[TBL] [Abstract][Full Text] [Related]
7. Urinary interleukin-1β levels among gynecological patients.
Woolery KT; Hoffman MS; Kraft J; Nicosia SV; Kumar A; Kruk PA
J Ovarian Res; 2014 Nov; 7():104. PubMed ID: 25403235
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic Performance of Risk of Ovarian Malignancy Algorithm Against CA125 and HE4 in Connection With Ovarian Cancer: A Meta-analysis.
Dayyani F; Uhlig S; Colson B; Simon K; Rolny V; Morgenstern D; Schlumbrecht M
Int J Gynecol Cancer; 2016 Nov; 26(9):1586-1593. PubMed ID: 27540691
[TBL] [Abstract][Full Text] [Related]
9. Providing Bionic Glycome as internal standards by glycan reducing and isotope labeling for reliable and simple quantitation of N-glycome based on MALDI- MS.
Qin W; Zhang Z; Qin R; Han J; Zhao R; Gu Y; Pan Y; Gu J; Ren S
Anal Chim Acta; 2019 Nov; 1081():112-119. PubMed ID: 31446948
[TBL] [Abstract][Full Text] [Related]
10. Serum glycome profiling: a biomarker for diagnosis of ovarian cancer.
Biskup K; Braicu EI; Sehouli J; Fotopoulou C; Tauber R; Berger M; Blanchard V
J Proteome Res; 2013 Sep; 12(9):4056-63. PubMed ID: 23889230
[TBL] [Abstract][Full Text] [Related]
11. Assessment of diagnostic utility of multivariate diagnostic models in differential diagnosis of ovarian tumors.
Horała A; Swiatly A; Lorek J; Kokot ZJ; Matysiak J; Nowak-Markwitz E
Ginekol Pol; 2018; 89(10):568-572. PubMed ID: 30393846
[TBL] [Abstract][Full Text] [Related]
12. Serum N-Glycome Characterization in Patients with Resectable Periampullary Adenocarcinoma.
Hamfjord J; Saldova R; Stöckmann H; Sandhu V; Bowitz Lothe IM; Buanes T; Lingjærde OC; Labori KJ; Rudd PM; Kure EH
J Proteome Res; 2015 Dec; 14(12):5144-56. PubMed ID: 26515733
[TBL] [Abstract][Full Text] [Related]
13. HE4: a new potential early biomarker for the recurrence of ovarian cancer.
Anastasi E; Marchei GG; Viggiani V; Gennarini G; Frati L; Reale MG
Tumour Biol; 2010 Apr; 31(2):113-9. PubMed ID: 20358424
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic Value of Serum Angiogenesis Markers in Ovarian Cancer Using Multiplex Immunoassay.
Horala A; Swiatly A; Matysiak J; Banach P; Nowak-Markwitz E; Kokot ZJ
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28075407
[TBL] [Abstract][Full Text] [Related]
15. Serum N-Glycome analysis reveals pancreatic cancer disease signatures.
Vreeker GCM; Hanna-Sawires RG; Mohammed Y; Bladergroen MR; Nicolardi S; Dotz V; Nouta J; Bonsing BA; Mesker WE; van der Burgt YEM; Wuhrer M; Tollenaar RAEM
Cancer Med; 2020 Nov; 9(22):8519-8529. PubMed ID: 32898301
[TBL] [Abstract][Full Text] [Related]
16. Approaches to the detection of ovarian cancer.
Høgdall E
Scand J Clin Lab Invest Suppl; 2016; 245():S49-53. PubMed ID: 27435369
[TBL] [Abstract][Full Text] [Related]
17. N-Glycome changes reflecting resistance to platinum-based chemotherapy in ovarian cancer.
Zahradnikova M; Ihnatova I; Lattova E; Uhrik L; Stuchlikova E; Nenutil R; Valik D; Nalezinska M; Chovanec J; Zdrahal Z; Vojtesek B; Hernychova L; Novotny MV
J Proteomics; 2021 Jan; 230():103964. PubMed ID: 32898699
[TBL] [Abstract][Full Text] [Related]
18. The serum glycome to discriminate between early-stage epithelial ovarian cancer and benign ovarian diseases.
Biskup K; Braicu EI; Sehouli J; Tauber R; Blanchard V
Dis Markers; 2014; 2014():238197. PubMed ID: 25183900
[TBL] [Abstract][Full Text] [Related]
19. Serum Anti-PDLIM1 Autoantibody as Diagnostic Marker in Ovarian Cancer.
Qiu C; Duan Y; Wang B; Shi J; Wang P; Ye H; Dai L; Zhang J; Wang X
Front Immunol; 2021; 12():698312. PubMed ID: 34489945
[TBL] [Abstract][Full Text] [Related]
20. [Ascites May Provide Useful Information for Diagnosis of Ovarian Cancer].
Stuchlíková E; Zahradníková M; Nenutil R; Valík D; Vojtěšek B; Novotný M; Hernychova L
Klin Onkol; 2017; 30(Supplementum1):187-190. PubMed ID: 28471203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
